Loading…
Based on limited metadata, the FDA issued a warning letter to Hangzhou Guoguang Touring Commodity Co., Ltd., a company involved in drug manufacturing or distribution, on December 14, 2018. Without access to the full warning letter text or subject line, the specific nature of the regulatory violations cannot be determined from the available information. The letter falls under FDA's drug product oversight authority, though the specific issuing office is not documented in this metadata summary. To understand the actual compliance issues and required corrective actions, review of the complete warning letter would be necessary.